Obseva (NASDAQ:OBSV) Stock Rating Lowered by Zacks Investment Research

Obseva (NASDAQ:OBSV) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. “

OBSV has been the topic of a number of other reports. Credit Suisse Group lowered their price target on shares of Obseva from $24.00 to $16.00 and set an “outperform” rating on the stock in a report on Monday. ValuEngine cut shares of Obseva from a “buy” rating to a “hold” rating in a report on Wednesday, May 8th. Wedbush restated an “outperform” rating and issued a $38.00 price target on shares of Obseva in a report on Thursday, July 18th. Finally, HC Wainwright set a $44.00 price target on shares of Obseva and gave the company a “buy” rating in a report on Wednesday, June 5th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $27.50.

Obseva stock traded up $0.26 during midday trading on Wednesday, hitting $9.36. 2,342 shares of the company’s stock were exchanged, compared to its average volume of 47,329. The company has a current ratio of 6.73, a quick ratio of 6.73 and a debt-to-equity ratio of 0.02. Obseva has a 12 month low of $8.83 and a 12 month high of $19.40. The business’s 50-day moving average price is $10.53. The firm has a market cap of $417.93 million, a P/E ratio of -4.90 and a beta of 0.93.

Obseva (NASDAQ:OBSV) last issued its earnings results on Thursday, May 9th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.09). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. As a group, sell-side analysts expect that Obseva will post -2.32 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in OBSV. Barclays PLC boosted its stake in Obseva by 331.1% in the 4th quarter. Barclays PLC now owns 10,118 shares of the company’s stock worth $128,000 after purchasing an additional 7,771 shares in the last quarter. Geode Capital Management LLC acquired a new stake in Obseva in the 4th quarter worth approximately $159,000. Jane Street Group LLC acquired a new stake in Obseva in the 4th quarter worth approximately $218,000. United Services Automobile Association boosted its stake in Obseva by 132.3% in the 4th quarter. United Services Automobile Association now owns 26,480 shares of the company’s stock worth $335,000 after purchasing an additional 15,080 shares in the last quarter. Finally, Wedbush Securities Inc. boosted its stake in Obseva by 86.1% in the 1st quarter. Wedbush Securities Inc. now owns 38,790 shares of the company’s stock worth $496,000 after purchasing an additional 17,950 shares in the last quarter. Institutional investors and hedge funds own 63.58% of the company’s stock.

About Obseva

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

See Also: Consumer behavior in bull markets

Get a free copy of the Zacks research report on Obseva (OBSV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.